Lisbibreath has been designed for the treatment of the recurrent upper respiratory infection.

An upper respiratory tract infection (URTI) is an illness caused by an acute infection, which involves the upper respiratory tract, including the nose, sinuses, pharynx, larynx or trachea.
The main causes are infections of viral  nature, and sometimes the cause is bacterial.
This illness is considered recurrent if it is treated  3 or more times during a calendar year.

In Lisbiotics we hypothesised that this repetition of the illness was due to a dysbiosis (unbalanced microbiome)  that affects  the correct response from the Immunitary System and therefore not being able to properly protect the respiratory tract.

In Lisbiotics we thought that a probiotic that will revert this dysbiosis and then improving the Respiratory Immunitary system would demonstrate this improvement by increasing the  Immunity markers and lowering inflammatory markers as the interleukins.